Auris Medical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Auris Medical and buy or sell other stocks, ETFs, and their options commission-free!

About EARS

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. 

CEO
Thomas Meyer, PhD
CEOThomas Meyer, PhD
Employees
13
Employees13
Headquarters
Hamilton, Hamilton
HeadquartersHamilton, Hamilton
Founded
2003
Founded2003
Employees
13
Employees13

EARS Key Statistics

Market cap
18.35M
Market cap18.35M
Price-Earnings ratio
-0.08
Price-Earnings ratio-0.08
Dividend yield
Dividend yield
Average volume
4.85K
Average volume4.85K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.6248
52 Week high$0.6248
52 Week low
$0.0501
52 Week low$0.0501

Stock Snapshot

Auris Medical(EARS) stock is priced at $3.21, giving the company a market capitalization of 18.35M. It carries a P/E multiple of -0.08.

Auris Medical(EARS) stock opened on 2026-02-10 at —. The price climbed to — and dipped to —.

The Auris Medical(EARS)'s current trading volume is 0, compared to an average daily volume of 4.85K.

In the last year, Auris Medical(EARS) shares hit a 52-week high of $0.62 and a 52-week low of $0.05.

In the last year, Auris Medical(EARS) shares hit a 52-week high of $0.62 and a 52-week low of $0.05.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.